Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

PlexusDx vs ReadyRx

PlexusDx
Graded #161

Higher grade

vs+0.10000000000000853
ReadyRx
Graded #168

Lower grade

The verdict

PlexusDx takes it — 67.7/100 to 67.6/100, but only just.

PlexusDx grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. PlexusDx (plexusdx.com) is a US GLP-1 telehealth platform offering compounded weight-loss medications with licensed providers in all 50 states. ReadyRx is close behind and may still be the better fit — see the factor split below.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valuePlexusDx +14
74
60
Dose & formulationEven
64
64
Clinical oversightReadyRx +5
74
79
Labs & monitoringReadyRx +12
52
64
FulfillmentReadyRx +5
78
83
Contract termsEven
55
55
PlexusDx · left barReadyRx · right bar

The numbers

MetricPlexusDxReadyRx
WeighScore67.7/10067.6/100
GradeCC
Scorecard rank#161#168
Semaglutide$149/mo (starting dose, compounded)$179/mo (starting dose, compounded)
Tirzepatide$249/mo (starting dose, compounded)$255/mo (starting dose, compounded)
CoverageAll 50 statesAll 50 states
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyInjection only
PlexusDx

Graded #161 · C

Strengths

  • Licensed providers available in all 50 states
  • Range of options including low-cost microdose GLP-1 from $129/mo
  • Optional Precision Peptide genetic panel adds a personalization angle
  • Independent clinician review via state-licensed telehealth platform
  • Compounded medications from state-licensed pharmacies

Where it loses points

  • Compounded medications only; no FDA-approved brand options
  • Specific compounding pharmacies not named
  • Genetic-panel upsell may not add clinical value for everyone
  • Tirzepatide pricing from $249/mo is higher than budget rivals
  • No insurance accepted
ReadyRx

Graded #168 · C

Strengths

  • LegitScript Certified — verifiable via the badge link in the footer
  • Batch lab testing covers the right QA metrics for injectables: potency, sterility, pH, and endotoxicity
  • Pricing shown publicly: $179/mo semaglutide, $255/mo tirzepatide

Where it loses points

  • Pharmacy partners not named — only described as 'FDA-registered compounding pharmacies'
  • Clinicians described as licensed and board-certified, but no names or credentials published
  • 5,000+ member figure comes from a directory listing, not an independent audit

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard